Test Dissolution for quality control of water-insoluble somatostatine analog

Background. Test Dissolution, which confirms the release of the active substance, is one of the most important criteria for the quality of tablets. This test significance is determined by potential correlation between the drug absorption in vivo and its release from the dosage form. It is especially difficult to develop the test Dissolution for substances that are poorly soluble in water.

Aim. To develop a test Dissolution method for cyphetrylin tablets, 60 mg and to study the release of active substance.

Materials and methods. In the work we used an original analogue of somatostatin – cyphetrylin, synthesized in the laboratory of chemical synthesis of N.N. Blokhin National Medical Research Center for Oncology of the Russian Ministry of Health. The test was developed for cyphetrylin tablets, 60 mg. The study was carried out on a dissolution tester Erweka series 700 (type II – Paddle (Erweka, Germany), using hydrochloric acid and isopropyl alcohol and their mixture as a dissolution medium. Quantitative determination of released cyphetrylin was carried out on a Agilent Cary® 100 recording spectrophotometer (Agilent Technologies, USA).

Results. Optimal conditions were selected to determine the release of cyphetrylin from tablets, 60 mg. Since cyphetrylin is insoluble in water, it is proposed to use a mixture of hydrochloric acid and isopropyl alcohol in a ratio 3:2 as a dissolution medium. It was shown that a paddle rotation speed of 100 rpm provides the release of cyphetrylin normalized quantity into the dissolution medium in 45 min. A method for cyphetrylin assay in a medium by direct spectrophotometry has been developed. Evaluation of the cyphetrylin release profile showed its gradual release from the tablets, which can be described by a linear relationship in accordance with the Higuchi equation.

Conclusion. As a result of the research, a test Dissolution procedure has been developed and the release profile of cyphetrylin from tablets, 60 mg, was assessed. Experimental data showed that in the selected conditions cyphetrylin release from the tablets is more than 80 % and meets the requirements of the Russian State Pharmacopoeia XV ed.

1. Sohail Arshad M., Zafar S., Yousef B. et al. A review of emerging technologies enabling improved solid oral dosage form manufacturing and processing. Adv Drug Deliv Rev 2021;178:113840. DOI: 10.1016/j.addr.2021.113840

2. Abend A., Curran D., Kuiper J. et al. Dissolution testing in drug product development: workshop summary report. AAPS J 2019;21(2):21. DOI: 10.1208/s12248-018-0288-4

3. Chen H., Wang R., McElderry J.D. Discriminative dissolution method development through a QbD approach. AAPS PharmSciTech 2023;24(8):255. DOI: 10.1208/s12249-023-02692-8

4. Russian State Pharmacopoeia, XV Edition. 2023. Available at: https://minzdrav.gov.ru/ministry/61/10/gosudarstvennayafarmakopeya-rossiyskoy-federatsii-xv-izdaniya. (In Russ.).

5. Pharmacopoeia of the Eurasian Economic Union. 2020. Available at: https://eec.eaeunion.org/upload/medialibrary/bd2/Farmakopeya-2020-t1_1.pdf?ysclid=lt8ai30j5x84425722. (In Russ.).

6. Grady H., Elder D., Webster G.K. et al. Industry’s view on using quality control, biorelevant, and clinically relevant dissolution tests for pharmaceutical development, registration, and commercialization. J Pharm Sci 2018;107(1):34–41. DOI: 10.1016/j.xphs.2017.10.019

7. Suarez-Sharp S., Abend A., Hoffelder T. et al. In vitro dissolution profiles similarity assessment in support of drug product quality: What, how, when-workshop summary report. AAPS J 2020; 22(4):74. DOI: 10.1208/s12248-020-00458-9

8. Gowthamarajan K.S., Singhdx S. Dissolution testing for poorly soluble drugs: A Continuing perspective. Dissolution Technologies 2010;8:24–32. DOI: 10.14227/DT170310P24

9. Grebenkin D.Yu., Stanishevskiy Ya.М., Shohin I.Е. Modern approaches of dissolution profile test (review). Razrabotka i registracija lekarstvennyh sredstv = Drug development and registration 2016;1(14):166–171. (In Russ.).

10. Ignаtieva Е.V., Shprakh Z.S., Yartseva I.V., Sanarova E.V. Test “Dissolution” as an integral part of quality complex evaluation of capsules with sekoisolariciresinol. Rossiysky bioterapevtichesky zhurnal = Russian Journal of Biotherapy 2019;1(18):95–100. (In Russ.). DOI: 10.17650/1726-9784-2019-18-1-95-100

11. Mudie D.M., Samiei N., Marshall D.J. et al. Selection of in vivo predictive dissolution media using drug substance and physiological properties. AAPS J 2020;22(2):34. DOI: 10.1208/s12248-020-0417-8

12. Shohin I.E., Grebenkin D.Y., Stanishevskii Y.M. et al. A brief review of the FDA dissolution methods database. Dissolution Technologies 2016;23(3):6–10. DOI: 10.14227/DT230316P6

13. Rohrs B. Dissolution method development of poorly soluble compounds. Dissolution Technologies 2001;8(3):1–5. DOI: 10.14227/DT080301P6

14. Smirnova L.I., Ustinkina S.V., Orlova O.L. et al. Drug with antitumor effect. RU2254139С1. 20.06.2005. (In Russ.).

15. Shprakh Z.S., Yartseva I.V., Smirnova L.I. et al. Synthesis and chemico-pharmaceutical characteristics of a somatostatin analog with antitumor activity. Himiko-farmacevticheskij zhurnal = Chemical and Pharmaceutical Journal 2012;48(3):19–22. (In Russ.). DOI: 10.30906/0023-1134-2014-48-3-19-22

16. Shprakh Z.S., Borisova L.M., Kiseleva M.P., Smirnova Z.S. Preclinical study of cyphetrylin antitunor efficiency on experimental animal tumors. Eksperimental’naja i klinicheskaja farmakologija = Experimental and clinical pharmacology 2019;48(3):19–22. (In Russ.). DOI: 10.30906/0869-2092-2019-82-8-27-31

17. Shprakh Z.S., Orlova O.L., Oborotova N.A., Bunyatyan N.D. Formulation and evaluation of Somatostatin analogue tablets. International Journal of Applied Pharmaceutics 2019;11(4):220–3. DOI: 10.22159/ijap.2019v11i4.32795

18. Shprakh Z.S. Analogue of the hypothalamic hormone cyphetrylin: preclinical study and the first experience of clinical use. Materials of the IV St. Petersburg International Oncological Forum “White Nights”: report abstract. Saint Petersburg, 2018. P. 169. (In Russ.).

19. Shprakh Z.S., Ignatieva E.V., Yartseva I.V. et al. Development and validation of cyphetrylin assay in tablets. Rossiysky bioterapevtichesky zhurnal = Russian Journal of Biotherapy 2016;15(3):55–61. (In Russ.). DOI: 10.17650/1726-9784-2016-15-3-55-61

20. Trucillo P. Drug carriers: A review on the most used mathematical models for drug release. Processes 2022;10(6):1094. DOI: 10.1016/j.addr.2021.11384